Business Context and Reporting Period
Company: Amgen Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2006
Business Overview: Amgen is a global biotechnology company operating in a single segment: human therapeutics. The company discovers, develops, manufactures, and markets products for supportive cancer care, nephrology, inflammation, and oncology. Principal products include Aranesp, Neulasta, NEUPOGEN, EPOGEN, and ENBREL (co-promoted with Wyeth). In late 2006, the company launched Vectibix, its first oncology therapeutic.
Key Financial Metrics
| Metric | 2006 | 2005 |
|---|---|---|
| Total Revenues | $14,268 million | $12,430 million |
| Product Sales | $13,858 million | $12,022 million |
| Net Income | $2,950 million | $3,674 million |
| Diluted EPS | $2.48 | $2.93 |
| Operating Income | $3,840 million | $4,848 million |
| Operating Margin | 28% | 40% |
| Research & Development (R&D) Expense | $3,366 million | $2,314 million |
| Cash, Cash Equivalents, & Marketable Securities | $6,277 million | $5,255 million |
| Total Debt | $9,012 million | $3,957 million |
| Stockholders' Equity | $18,964 million | $20,451 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 15% to $14.3 billion, driven primarily by sales growth in Aranesp (26%), Neulasta/NEUPOGEN (12%), and ENBREL (12%).
- Profitability Decline: Net income decreased 20% to $2.95 billion. Operating income dropped 21% to $3.84 billion. This decline was primarily due to a $1.23 billion write-off of acquired in-process research and development (IPR&D) from the Abgenix and Avidia acquisitions, increased R&D spending, and the adoption of SFAS No. 123(R) requiring stock option expensing.
- Debt Increase: Total debt more than doubled to $9.0 billion. This resulted from the issuance of $5.0 billion in convertible notes (2011 and 2013 maturities) in February 2006 to fund stock repurchases and general corporate purposes.
- Acquisitions: Completed the acquisition of Abgenix (April 2006) and Avidia (October 2006), adding Vectibix to the product portfolio and expanding the R&D pipeline.
Guidance, Outlook, and Risks
- Outlook: Management expects R&D expenses to increase in 2007, though not to the extent of 2006, due to the continuation of nine "mega-site" clinical trials. Product sales growth is expected to continue, driven by Aranesp, Neulasta, and ENBREL, with Vectibix contributing to growth.
- Competition: The company faces increasing competition, particularly in Europe where biosimilar products for erythropoietin and G-CSF are expected to be approved in 2007. In the U.S., Roche is expected to launch a pegylated erythropoietin product in 2007 despite ongoing patent litigation.
- Reimbursement Risks: Sales are heavily dependent on third-party reimbursement. Changes in Medicare reimbursement methodologies (e.g., ASP+6%) and potential bundled payment systems for dialysis could negatively impact sales. The company also faces risks related to the "Claims Monitoring Policy" regarding hemoglobin targets for dialysis patients.
- Legal Proceedings: Significant litigation includes patent disputes with Roche regarding peg-EPO, Average Wholesale Price (AWP) litigation involving multiple states and the federal government, and product liability claims.
- Manufacturing: The company relies heavily on its Puerto Rico facility for formulation, fill, and finish of principal products, creating a concentration risk regarding natural disasters or production failures.
Investor Verification Checklist
- Acquisition Impact: Verify the long-term commercial viability of the Abgenix and Avidia acquisitions, specifically the performance of Vectibix and the pipeline candidates.
- Patent Litigation: Monitor the outcome of the patent infringement lawsuit against Roche regarding peg-EPO, which could significantly impact the nephrology segment.
- Biosimilar Threats: Assess the timeline and market impact of biosimilar approvals in the European Union for Aranesp and Neulasta/NEUPOGEN.
- Reimbursement Policy: Track changes in Medicare reimbursement rates and the potential implementation of bundled payment systems for dialysis drugs.
- Debt Structure: Review the terms of the $5 billion convertible notes issued in 2006 and the potential dilution or cash outflow upon conversion or maturity.
- Manufacturing Concentration: Evaluate the contingency plans for the Puerto Rico manufacturing facility, which handles the majority of product finishing.